Orig3n Stock

orig3n.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $85.64MM

Orig3n is a developer of DNA tests designed to help people understand the links between their genes and how their minds and bodies work, and researcher of cellular science to develop personalized therapies for repairing tissue damage and disease.

Register for Details

For more details on financing and valuation for Orig3n, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Orig3n.

Register Today

Team

Management Team

Robin Smith
Co-Founder & Chief Executive Officer
Marcie Glicksman Ph.D
Chief Scientific Officer
Kate Blanchard
Co-Founder & Chief Operating Officer
Michael Fang MD
Chief Medical Officer

Board Members

Justin Xiang Ph.D
Syno Capital
Byron Smith
Mountain Group Partners
Angela Ruggiero

Other companies like Orig3n in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

State suspends COVID-19 testing at Orig3n, Boston lab responsible for at least 383 false positive results - The Boston Globe
A state investigation found the lab “put patients at immediate risk of harm.”
Updated on: Sep 27, 2023